Literature DB >> 31211599

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

C Louwrens Braal1, Jos H Beijnen1, Stijn L W Koolen1, Esther Oomen-de Hoop1, Neeltje Steeghs1, Agnes Jager1, Alwin D R Huitema1, Ron H J Mathijssen1.   

Abstract

Entities:  

Year:  2019        PMID： 31211599     DOI： 10.1200/JCO.19.00418

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Precision Dosing of Targeted Therapies Is Ready for Prime Time.

Authors:  Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer
Journal:  Clin Cancer Res       Date:  2021-09-21       Impact factor: 12.531

2.  The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.

Authors:  Jeanine Marie Nardin; Werner Schroth; Thais Abreu Almeida; Thomas Mürdter; Solane Picolotto; Evelyn Castillo Lima Vendramini; Reiner Hoppe; Jenifer Primon Kogin; Diandra Miqueleto; Silvia Dark Robaskievicz de Moraes; Matthias Schwab; Roberto Flavio Pecoits-Filho; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  Clin Transl Sci       Date:  2019-11-09       Impact factor: 4.689

3.  Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.

Authors:  Clara Inkyung Lee; Siew Kee Low; Ricardo Maldonado; Peter Fox; Bavanthi Balakrishnar; Sally Coulter; Peter de Bruijn; Stijn L W Koolen; Bo Gao; Jodi Lynch; Nicholas Zdenkowski; Rina Hui; Christopher Liddle; Ron H J Mathijssen; Nicholas Wilcken; Mark Wong; Howard Gurney
Journal:  Breast       Date:  2020-10-21       Impact factor: 4.380

4.  Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial.

Authors:  C Louwrens Braal; Anne Kleijburg; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen; Isaac Corro Ramos; Pim Wetzelaer; Carin A Uyl-de Groot
Journal:  Clin Drug Investig       Date:  2022-01-12       Impact factor: 2.859

5.  Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.

Authors:  C Louwrens Braal; Agnes Jager; Esther Oomen-de Hoop; Justin D Westenberg; Koen M W T Lommen; Peter de Bruijn; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Martine F Thijs-Visser; Robbert J van Alphen; Liesbeth E M Struik; Hanneke J M Zuetenhorst; Ron H J Mathijssen; Stijn L W Koolen
Journal:  Clin Pharmacokinet       Date:  2021-11-17       Impact factor: 6.447

6.  (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study.

Authors:  Thais Almeida; Werner Schroth; Jeanine Nardin; Thomas E Mürdter; Stefan Winter; Solane Picolotto; Reiner Hoppe; Jenifer Kogin; Elisa Gaio; Angela Dasenbrock; Raquel Cristina Skrsypcsak; Lucia de Noronha; Matthias Schwab; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  J Pers Med       Date:  2022-03-22

7.  Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.

Authors:  C Louwrens Braal; Justin D Westenberg; Sanne M Buijs; Steven Abrams; Tessa A M Mulder; Ron H N van Schaik; Stijn L W Koolen; Agnes Jager; Ron H J Mathijssen
Journal:  Breast Cancer Res Treat       Date:  2022-07-16       Impact factor: 4.624

8.  Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups.

Authors:  Anna Mueller-Schoell; Robin Michelet; Lena Klopp-Schulze; Madelé van Dyk; Thomas E Mürdter; Matthias Schwab; Markus Joerger; Wilhelm Huisinga; Gerd Mikus; Charlotte Kloft
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.

Authors:  Anabel Beatriz Sanchez-Spitman; Dirk-Jan A R Moes; Jesse J Swen; Vincent O Dezentjé; Diether Lambrechts; Patrick Neven; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-29       Impact factor: 3.333

10.  Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.

Authors:  Lena Klopp-Schulze; Anna Mueller-Schoell; Patrick Neven; Stijn L W Koolen; Ron H J Mathijssen; Markus Joerger; Charlotte Kloft
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.